Shaddock peel oil with functions of reducing weight and reducing blood fat

Through the preparation and application of pomelo peel oil, its phytosterols, flavonoids and polyphenol components have been used to solve the treatment problems of obesity and hyperlipidemia, and effective weight and blood lipid reduction, providing a pure natural and safe lipid reduction strategy. .

CN119020091APending Publication Date: 2024-11-26GUANGXI MEDICAL UNIVERSITY
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411101693.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-12
Publication Date
2024-11-26

AI Technical Summary

Technical Problem

The prevalence and severity of obesity and hyperlipidemia leads to the high incidence of a variety of chronic diseases, the existing drug treatment has side effects, and the lack of pure natural and safe lipid-lowering strategies.

Method used

By preparing pomelo peel oil as a functional vegetable oil, active ingredients such as phytosterols, flavonoids and polyphenols in pomelo peel are extracted using petroleum ether, and are used as drugs or health products to prevent and treat obesity and hyperlipidemia.

Benefits of technology

Pomelo peel oil effectively reduces the weight, fat accumulation and blood lipid levels of mice, reduces fat growth and serum triglycerides, total cholesterol and low-density lipoprotein cholesterol, providing scientific basis for dietary intervention in obesity and hyperlipidemia, and No obvious side effects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119020091A_ABST
    Figure CN119020091A_ABST
Patent Text Reader

Abstract

The invention relates to shaddock peel oil with functions of reducing weight and reducing blood fat. The research finds that the prepared natural shaddock peel oil is rich in various functional components, such as phytosterol, fatty acid, flavone, polyphenol and the like, and has the effects of effectively reducing the weight, fat accumulation and blood fat level of high-fat fed mice and improving the immunity of the mice. An important scientific basis is provided for preventing and treating diet intervention obesity, hyperlipidemia and cardiovascular and cerebrovascular diseases.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of natural products, and in particular to a grapefruit peel oil having weight-reducing and blood-lipid-lowering functions. Background Art

[0002] In recent years, with the gradual improvement of living standards, residents' intake of high-carbohydrate and high-fat foods has increased significantly, which has had a profound impact on the obesity problem in the world and my country. According to statistics from the World Health Organization, 39% of adults are overweight and 13% of adults are obese worldwide. This data highlights the prevalence and severity of the obesity problem. Obesity not only affects a person's appearance and self-confidence, but more importantly, it is a major risk factor for a variety of chronic diseases. Obesity is one of the main risk factors for chronic diseases such as hypertension, insulin resistance, diabetes, and cardiovascular disease. Specifically: Hypertension: Obesity is an independent risk factor for hypertension. When the body becomes fat, the heart needs to eject more blood to meet the body's metabolic needs, thereby causing blood pressure to rise. Diabetes: Obesity can cause various endocrine abnormalities, the most common of which is insulin resistance, which is one of the important causes of type 2 diabetes. Hyperlipidemia: Most obese friends have lipid metabolism abnormalities, which are prone to abnormal triglyceride levels, increasing the risk of serious diseases such as acute severe pancreatitis. Cardiovascular and cerebrovascular diseases: obese people are prone to increased heart load, and their blood is thicker and they often have various chronic diseases, which makes them more likely to suffer from various cardiovascular and cerebrovascular diseases. Tumors: obesity also leads to a high incidence of many cancers, such as rectal cancer and colon cancer.

[0003] In my country, the number of obese people is as high as 340 million, which has seriously threatened the health of the Chinese people. According to the data released by the China Obesity Map, 34.8% of adult subjects in my country are overweight and 14.1% are obese. In addition, there are differences in the peak age of obesity in men and women. The obesity rate of men reaches its peak at 35 to 39 years old, while the obesity rate of women reaches its peak at 70 to 74 years old.

[0004] Hyperlipidemia is mainly manifested as an abnormal increase in blood lipid or lipoprotein content. It is the main complication of obesity and can induce cardiovascular disease. Hyperlipidemia is mainly caused by an unhealthy lifestyle and diet. In recent years, high-calorie diets have become more and more common, resulting in 160 million people with abnormal blood lipids in China. Whether it is obesity or hyperlipidemia, although it may not have a significant impact on the patient's health in the early stage of onset, as the disease progresses, if the weight and blood lipids are abnormal for a long time, multiple organs and systems such as the cardiovascular, respiratory and endocrine systems may be affected. Therefore, how to prevent the occurrence of obesity and hyperlipidemia and delay the development of the patient's condition has become the focus and difficulty of research in the medical field. At present, the main drugs for treating hyperlipidemia are statins such as atorvastatin and simvastatin. Although they can lower blood lipids and regulate lipid metabolism, long-term use may cause certain side effects, such as liver and kidney damage. In recent years, researchers have found that many oils naturally present in food (such as soybean germ oil, tomato seed oil, peony seed oil, hawthorn seed oil) have a certain improvement effect on the body's lipid metabolism because they are rich in active ingredients (such as polyunsaturated fatty acids, phytosterols, oryzanol and flavonoids, etc.). Therefore, the discovery of natural, safe and lipid-lowering natural functional plant oils is expected to become a new strategy to achieve weight loss and lipid-lowering through dietary adjustment.

[0005] Pomelo is a tree plant of the Rutaceae family, Citrus genus, widely distributed in southern my country. Among them, Shatian pomelo is one of the symbols of Guangxi's characteristic agricultural products. Shatian pomelo is rich in nutrients and contains a variety of nutrients and plant active ingredients. At present, people mainly eat pomelo pulp or process it deeply, while pomelo peel is often abandoned as a waste, resulting in serious waste of resources. If these resources can be integrated and effectively utilized, it will not only respond to the country's call for strict diligence and thrift, but also conform to the concept of "turning waste into treasure", which will greatly improve the comprehensive utilization rate of pomelo peel and obtain considerable economic benefits. Summary of the invention

[0006] The first object of the present invention is to provide a use of grapefruit peel oil in preparing a product for preventing, treating and / or curing obesity and hyperlipidemia in view of the above problems.

[0007] In order to achieve the above object, the technical solution adopted by the present invention is:

[0008] Application of grapefruit peel oil in preparing products for preventing, treating and / or curing obesity and hyperlipidemia, the preparation method of the grapefruit peel oil comprising the following steps:

[0009] (1) Grinding grapefruit peel to obtain grapefruit peel powder;

[0010] (2) Extracting the grapefruit peel powder with petroleum ether for 24-36 hours, combining the two petroleum ether extracts and evaporating them in a rotary evaporator under vacuum, and collecting the upper clear oil to obtain grapefruit peel oil.

[0011] It is further stated that the products include medicines, functional foods and health products.

[0012] It is further described that the material-liquid ratio of the grapefruit peel powder to petroleum ether is 1 g: 10-20 mL.

[0013] It is further described that the grapefruit peel powder is extracted with petroleum ether at least twice.

[0014] It is further described that the particle size of the pomelo peel powder is 30-50 mesh.

[0015] It is further explained that the conditions for the vacuum evaporation are a temperature of 45-60° C., a rotation speed of 5000-7000 rpm, and a time of 5-15 min.

[0016] The invention also provides a product for preventing, treating and / or curing obesity and hyperlipidemia, wherein the product uses grapefruit peel oil as a main active ingredient.

[0017] The present invention also provides a product for preventing, treating and / or curing obesity and hyperlipidemia, wherein the product uses grapefruit peel oil and ginkgo leaf extract as main active ingredients.

[0018] Further description, a product for preventing, treating and / or curing obesity and hyperlipidemia, wherein the mass ratio of the grapefruit peel oil to the passion fruit seed oil is 1:1.

[0019] Generally speaking, drugs and health products are used clinically after being prepared into preparations. The pharmaceutical composition and health product of the present invention can be prepared according to methods known in the art as pharmaceutical compositions and health products. The pharmaceutical composition and health product of the present invention can be combined with one or more pharmaceutically acceptable solid or liquid excipients and / or adjuvants to prepare any dosage form suitable for human or animal use.

[0020] The pharmaceutical composition, health product of the present invention or the pharmaceutical composition or health product containing the same can be administered in a unit dosage form, and the administration route can be enteral or parenteral, such as oral, intravenous, intramuscular, subcutaneous, nasal, oral mucosa, eyes, lungs and respiratory tract, skin, vagina, rectum, etc.

[0021] The dosage form can be a liquid dosage form, a solid dosage form or a semisolid dosage form. Liquid dosage forms can be solutions (including true solutions and colloidal solutions), emulsions (including o / w types, w / o types and multiple emulsions), suspensions, injections (including water injections, powder injections and infusions), eye drops, nasal drops, lotions and liniments, etc.; solid dosage forms can be tablets (including ordinary tablets, enteric-coated tablets, lozenges, dispersible tablets, chewable tablets, effervescent tablets, orally disintegrating tablets), capsules (including hard capsules, soft capsules, enteric-coated capsules), granules, powders, micropills, dropping pills, suppositories, films, patches, aerosols (powders), sprays, etc.; semisolid dosage forms can be ointments, gels, pastes, etc.

[0022] The pharmaceutical composition and health care product of the present invention can be made into common preparations, sustained-release preparations, controlled-release preparations, targeted preparations and various microparticle delivery systems. In order to make the pharmaceutical composition and health care product of the present invention into tablets, various excipients known in the art can be widely used, including diluents, binders, wetting agents, disintegrants, lubricants and glidants. The diluent may be starch, dextrin, sucrose, glucose, lactose, mannitol, sorbitol, xylitol, microcrystalline cellulose, calcium sulfate, calcium hydrogen phosphate, calcium carbonate, etc.; the wetting agent may be water, ethanol, isopropanol, etc.; the adhesive may be starch slurry, dextrin, syrup, honey, glucose solution, microcrystalline cellulose, acacia slurry, gelatin slurry, sodium carboxymethyl cellulose, methyl cellulose, hydroxypropyl methyl cellulose, ethyl cellulose, acrylic resin, carbomer, polyvinyl pyrrolidone, polyethylene glycol, etc.; the disintegrant may be dry starch, microcrystalline cellulose, low-substituted hydroxypropyl cellulose, cross-linked polyvinyl pyrrolidone, cross-linked sodium carboxymethyl cellulose, sodium carboxymethyl starch, sodium bicarbonate and citric acid, polyoxyethylene sorbitan fatty acid ester, sodium dodecyl sulfate, etc.; the lubricant and glidant may be talc, silicon dioxide, stearate, tartaric acid, liquid paraffin, polyethylene glycol, etc.

[0023] The tablets can be further made into coated tablets, such as sugar-coated tablets, film-coated tablets, enteric-coated tablets, or double-layer tablets and multi-layer tablets.

[0024] In order to prepare the dosing unit into a capsule, the active ingredient pharmaceutical composition of the present invention and the health product can be mixed with a diluent and a glidant, and the mixture can be directly placed in a hard capsule or a soft capsule. The active ingredient pharmaceutical composition of the present invention and the health product can also be first made into granules or pellets with a diluent, a binder, and a disintegrant, and then placed in a hard capsule or a soft capsule. The diluents, binders, wetting agents, disintegrants, and glidants used to prepare the pharmaceutical composition of the present invention and the health product tablets can also be used to prepare the capsules of the pharmaceutical composition of the present invention and the health product.

[0025] In order to prepare the pharmaceutical composition and health care product of the present invention into an injection, water, ethanol, isopropanol, propylene glycol or a mixture thereof can be used as a solvent and an appropriate amount of a solubilizer, a cosolvent, a pH adjuster, and an osmotic pressure regulator commonly used in the art can be added. The solubilizer or cosolvent can be poloxamer, lecithin, hydroxypropyl-β-cyclodextrin, etc.; the pH adjuster can be phosphate, acetate, hydrochloric acid, sodium hydroxide, etc.; the osmotic pressure regulator can be sodium chloride, mannitol, glucose, phosphate, acetate, etc. If a lyophilized powder injection is prepared, mannitol, glucose, etc. can also be added as a support agent.

[0026] In addition, if necessary, colorants, preservatives, spices, flavoring agents or other additives may be added to the medicines and health care product preparations.

[0027] When the product is a functional food, in order to improve the application scope of the functional food, it also includes a food-acceptable carrier and / or auxiliary material, such as a diluent, excipient, filler, binder, wetting agent, disintegrant, absorption promoter, sweetener, flavoring agent, or a combination thereof. And the form of the functional food includes but is not limited to decoction, beverage, candy, oral liquid, capsule, tablet and powder.

[0028] Due to the adoption of the above technical solution, the present invention has the following beneficial effects:

[0029] The present invention uses petroleum ether to prepare grapefruit peel into grapefruit peel oil. It is found through research that the prepared natural grapefruit peel oil is rich in various functional ingredients, such as plant sterols, fatty acids, flavonoids, polyphenols, etc., and can effectively reduce the body weight, fat accumulation and blood lipid levels of high-fat fed mice, providing an important scientific basis for dietary intervention in obesity and hyperlipidemia and prevention and treatment of cardiovascular and cerebrovascular diseases. The present invention is the first to use grapefruit peel oil to treat obesity and hyperlipidemia. Compared with the lipid-lowering drug cholestyramine, grapefruit peel oil can not only reduce serum triglyceride (TG), total cholesterol (TC) and low-density lipoprotein cholesterol (LDLC) values, but also effectively reduce fat accumulation and weight gain. BRIEF DESCRIPTION OF THE DRAWINGS

[0030] Figure 1 It is a curve chart of weight changes of mice in each treatment experimental group as the treatment time increases in Example 3 of the present invention.

[0031] Figure 2 This is a comparison chart of epididymal fat and peripheral fat weights of mice in various treatment experimental groups in Example 3 of the present invention.

[0032] Figure 3 It is a comparison diagram of liver sections of mice in various treatment experimental groups in Example 3 of the present invention. DETAILED DESCRIPTION

[0033] In order to make the purpose, technical solution and advantages of the present invention more clearly understood, the present invention is further described in detail below in conjunction with the embodiments and drawings. It should be understood that the specific embodiments described herein are only used to explain the present invention and are not intended to limit the present invention.

[0034] Current research has proven that the value of grapefruit peel oil is very worthy of promotion. The specific research is recorded in the following example analysis.

[0035] Example 1: Preparation of grapefruit peel oil

[0036] The specific steps are as follows:

[0037] Grind the grapefruit peel into powder using a grinder, pass through a 40-mesh sieve and mix thoroughly.

[0038] Soak grapefruit peel powder and petroleum ether in a solid-liquid ratio of 1:10 for 24 hours, filter the mixture and take the first filtrate.

[0039] The residue after soaking was soaked again with petroleum ether at a solid-liquid ratio of 1:10 for 36 hours, filtered, and the second filtrate was taken.

[0040] The two petroleum ether extracts were combined and evaporated in a rotary evaporator under vacuum (temperature 50° C., rotation speed 6000 rpm, 10 min), and the supernatant oil was collected to obtain grapefruit peel oil.

[0041] Example 2: Chemical composition analysis of the grapefruit peel oil prepared in Experimental Example 1

[0042] (1) Analysis of phytosterol components and their contents

[0043] The results of the analysis of grapefruit peel oil by gas chromatography are shown in Table 1. There are 6 main identifiable phytosterols in grapefruit peel oil, among which β-sitosterol, δ7-avenosterol and campesterol are the main phytosterols, with relative percentages of 47.19%, 27.28% and 9.54% respectively. The β-sitosterol content in grapefruit peel oil is higher than that in many common edible oils (such as wheat germ oil, soybean oil and garlic oil).

[0044] Table 1 Composition and relative content of phytosterols in grapefruit peel oil

[0045] Types of Phytosterols Average content (mg / 100g) Relative percentage content (%) Campesterol 218.84±15.28 9.54 Stigmasterol 144.91±14.20 6.31 β-Sitosterol 1082.95±108.26 47.19 Stigmasterol 45.99±4.74 2.00 Δ7-stigmasterol 169.50±23.47 7.68 δ7-Avenasterenol 632.90±65.99 27.28

[0046] (2) Analysis of fatty acid composition and content

[0047] The fatty acid analysis of grapefruit peel oil was performed by gas chromatography. As shown in Table 2, the relative percentage of saturated fatty acids in grapefruit peel oil is 10.6%; the relative percentage of unsaturated fatty acids is 89.40%, of which monounsaturated fatty acids account for 24.64% and polyunsaturated fatty acids account for 64.76%, mainly linoleic acid and oleic acid, followed by octadecatrienoic acid and palmitic acid.

[0048] Table 2 Fatty acid composition and relative content in grapefruit peel oil

[0049]

[0050]

[0051] (3) Analysis of total flavonoid components and their contents

[0052] The absorbance was measured by spectrophotometry at a wavelength of 750 nm, and a standard curve was drawn with rutin standard to obtain a linear regression equation of y = 0.02758x + 0.0037, R 2 =0.9978, and then compared with the standard curve, it was found that the total flavonoid content in grapefruit peel oil was 234.50 mg / 100 g, which is several hundred times the flavonoid content in ordinary edible oils (the total flavonoid content in soybean oil is 1.31 mg / 100 g, and the total flavonoid content in corn oil is 1.01 mg / 100 g).

[0053] (4) Analysis of total polyphenol components and their contents

[0054] The absorbance was measured by spectrophotometry at a wavelength of 750 nm, and a standard curve was drawn with rutin standard to obtain a linear regression equation of y = 0.0175x + 0.02468, R 2 =0.9995, and then compared with the standard curve, the total phenol content in the grapefruit peel oil sample was 3370.00 mg / 100 g, which is several hundred times the polyphenol content in ordinary edible oils (the total polyphenol content in rapeseed oil is 13.983 mg / 100 g, and the total polyphenol content in corn oil is 12.88 mg / 100 g).

[0055] Example 3: Pomelo peel oil weight loss and blood lipid reduction test

[0056] (1) Mouse experiments:

[0057] ①Animal experiment design:

[0058] Forty-six C57BL / 6J mice (4 weeks old, male, 18-20 g) were randomly divided into 5 groups, namely: low-fat diet control group (LFD, n=10), high-fat diet group (HFD, n=10), low-dose grapefruit peel oil experimental group (LPPO, n=8), high-dose grapefruit peel oil experimental group (HPPO, n=8), and positive control group (PC, n=10).

[0059] ② Preparation of mouse food:

[0060] As shown in Table 3, the low-fat diet control group (LFD) was composed of a mixture of casein, L-cystine, sucrose, lard, soybean oil, minerals, vitamins, cellulose, etc.; the high-fat diet control group (HFD): the fat energy supply accounted for 60%; the low-dose grapefruit peel oil experimental group (LPPO): on the basis of HFD, grapefruit peel oil was used to replace 30% of the lard in the high-fat diet; the high-dose grapefruit peel oil experimental group (HPPO): on the basis of HFD, grapefruit peel oil was used to replace 60% of the lard in the high-fat diet; the positive control group (PC): on the basis of HFD, 1% (weight percentage) of cholestyramine was added.

[0061] Table 3 Food ration table

[0062]

[0063]

[0064] ③Experimental results:

[0065] 1) Effect of grapefruit peel oil on body weight of obese mice

[0066] from Figure 1 As shown in Table 4, at week 0, the body weights of mice in each group were at similar levels. After 12 weeks of intervention, HFD feeding successfully induced obesity in mice. Compared with the HFD group, the body weights of mice in the LPPO and HPPO groups were significantly reduced by 15.34% and 24.48% (P<0.05). The weight loss effect of LPPO was comparable to that of the positive control, and the weight loss effect of HPPO was even better than that of the positive control, indicating that grapefruit peel oil can reduce the body weight of mice in a dose-dependent manner.

[0067] 2) Effects of grapefruit peel oil on adipose tissue in obese mice

[0068] from Figure 2 As shown in Table 4, HFD significantly increased the weight of epididymal fat, peripheral fat and total white fat in mice. Compared with the HFD group, PPO significantly reduced the accumulation of epididymal fat, peripheral fat and total white fat in mice, and showed a significant dose effect (P<0.05).

[0069] Table 4 Comparison of body weight and fat weight of mice in each treatment experimental group (g)

[0070] LFD HFD LPPO HPPO PC P Week 0 Weight 18.75±0.82 19.30±0.92 19.25±0.91 18.86±1.07 19.21±0.60 0.5418 Week 12 Weight 26.26±1.53c 37.86±4.16a 32.05±3.90b 28.59±2.00c 33.55±2.29b <0.001 Weight gain 7.51±1.29c 18.56±4.04a 12.80±3.26b 9.73±1.49c 14.34±1.90b <0.001 Epididymal fat weight 0.32±0.08d 2.17±0.53a 1.64±0.57b 1.13±0.29c 1.63±0.47b <0.0001 Peripheral fat weight 0.14±0.04c 0.97±0.37a 0.75±0.30ab 0.42±0.10b 0.80±0.28ab <0.0001

[0071] 3) Effect of grapefruit peel oil on liver fat in obese mice

[0072] from Figure 3 H&E staining results showed that HFD significantly increased the number and volume of liver lipid droplet vacuoles, while citrus oil could reduce lipid droplet vacuoles in a dose-dependent manner. Oil red staining results showed that HFD significantly increased the oil red staining area of ​​liver sections, indicating that the fat content of the liver increased significantly, while citrus oil intervention significantly reduced the oil red staining area of ​​liver sections. These results indicate that HFD significantly increases fat accumulation in the liver, while citrus oil can significantly reduce the fat content of the liver in a dose-dependent manner.

[0073] 4) Effect of grapefruit peel oil on blood lipids in obese mice

[0074] As shown in Table 5, HFD feeding significantly increased the levels of serum triglycerides (TG), total cholesterol (TC) and low-density lipoprotein cholesterol (LDLC) in mice. Compared with HFD, LPPO, HPPO and PC significantly reduced serum TG levels (P<0.05), and there was no difference with the LFD group, indicating that grapefruit peel oil can effectively reduce serum triglycerides to normal dietary levels. In addition, LPPO and HPPO can reduce serum TC levels in a dose-dependent manner (P<0.05), and reduce serum LDLC levels by 16.37% and 33.05% (P<0.05), which is equivalent to the positive control. The above results show that grapefruit peel oil can significantly improve the serum lipid levels of high-fat fed mice.

[0075] Table 5 Comparison of blood lipids in mice in each treatment experimental group

[0076]

[0077] The above results show that grapefruit peel oil is rich in a variety of plant active ingredients, including phytosterols, flavonoids, polyphenols, and unsaturated fatty acids, which can effectively reduce the body weight, fat accumulation and blood lipid levels of high-fat fed mice, providing an important scientific basis for dietary intervention in the prevention and treatment of obesity, hyperlipidemia and cardiovascular and cerebrovascular diseases.

[0078] Experimental Example 4: Effect of Combination of Grapefruit Peel Oil and Passion Fruit Seed Oil on Lowering Blood Lipids

[0079] Preparation method of passion fruit seed oil: crush the dried passion fruit seeds through a 50-mesh sieve, add petroleum ether to the passion fruit seed powder at a solid-liquid ratio of 1:10 (g / mL), extract at 25°C for 24 hours, repeat the extraction 3 times, combine the extracts, and concentrate by rotary evaporation to obtain the oil.

[0080] The experimental method is the same as that of Experimental Example 3, except that the grapefruit peel oil in the mouse diet (LPPO) is replaced by a combination of grapefruit peel oil and passion fruit seed oil. The dosage ratio (mass ratio) of the grapefruit peel oil to the passion fruit seed oil is 1:1, and a mouse diet containing the same dose of grapefruit peel oil alone (PPO) and a mouse diet containing the same dose of passion fruit seed oil alone (PFSO) are used as controls.

[0081] The experimental results showed that the combination of grapefruit peel oil and passion fruit seed oil (PPO+PFSO) increased the weight loss effect of PPO+PFSO by 15.06% and 17.87% compared with PPO and PFSO, respectively. Compared with PPO and PFSO, PPO+PFSO mice increased the effect of reducing serum triglycerides (TG) by 25.20% and 23.33%, the effect of reducing serum total cholesterol (TC) by 16.19% and 14.36%, and the effect of reducing serum low-density lipoprotein cholesterol (LDLC) by 25.00% and 21.69%.

[0082] HFD PPO PFSO PPO+PFSO P Weight gain (g) 19.62±2.33a 16.34±2.51b 16.90±3.51b 13.88±2.03c 0.002 TG (mmol / L) 1.45±0.20a 1.23±0.21b 1.20±0.18b 0.92±0.13c 0.008 TC(mmol / L) 6.25±0.32a 5.62±0.37b 5.50±0.25b 4.71±0.45c <0.001 HDLC(mmol / L) 2.45±0.34 2.36±0.66 2.41±0.38 2.71±0.41 0.204 LDLC(mmol / L) 3.52±0.48a 2.60±0.65b 2.49±0.58b 1.95±0.40c <0.001

[0083] This shows that the combination of grapefruit peel oil and passion fruit seed oil has a synergistic effect of reducing weight and lowering blood lipids.

[0084] It is also stated that the active ingredients of passion fruit seed oil mainly include polyphenols, flavonoids, unsaturated fatty acids, etc., which have no side effects in the body.

[0085] In summary, the combination of grapefruit peel oil and passion fruit seed oil provides a new idea for the prevention and treatment of obesity and hyperlipidemia.

[0086] The above description is a detailed description of the preferred embodiments of the present invention, but the embodiments are not intended to limit the scope of the patent application of the present invention. All equivalent changes or modifications completed under the technical concept suggested by the present invention should fall within the scope of the patent covered by the present invention.

Claims

1. Use of grapefruit peel oil in preparing products for preventing, treating and / or treating obesity and hyperlipidemia, characterized in that: The preparation method of the grapefruit peel oil comprises the following steps: (1) Grinding grapefruit peel to obtain grapefruit peel powder; (2) Extracting the grapefruit peel powder with petroleum ether for 24-36 hours, combining the two petroleum ether extracts and evaporating them in a rotary evaporator under vacuum, and collecting the upper clear oil to obtain grapefruit peel oil.

2. The use according to claim 1, characterized in that: The products include medicines, functional foods and health products.

3. The use according to claim 1, characterized in that: The material-liquid ratio of the pomelo peel powder to petroleum ether is 1 g:10-20 mL.

4. The use according to claim 1, characterized in that: The grapefruit peel powder was extracted with petroleum ether at least twice.

5. The use according to claim 1, characterized in that: The particle size of the pomelo peel powder is 30-50 meshes.

6. The use according to claim 1, characterized in that: The vacuum evaporation conditions are as follows: temperature 45-60° C., rotation speed 5000-7000 rpm, and time 5-15 min.

7. A product for preventing, treating and / or treating obesity and hyperlipidemia, characterized in that: The product uses grapefruit peel oil as the main active ingredient.

8. A product for preventing, treating and / or treating obesity and hyperlipidemia, characterized in that: The product uses grapefruit peel oil and ginkgo leaf extract as main active ingredients.

9. A product for preventing, treating and / or curing obesity and hyperlipidemia according to claim 8, characterized in that: The mass ratio of the grapefruit peel oil to the passion fruit seed oil is 1:1.